welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
study id #: NCT00675636
condition: Colorectal Cancer, Hereditary Nonpolyposis Colorectal Cancer, Precancerous Condition
RATIONALE: Gathering medical and family history information from patients and family members may help doctors better understand hereditary colorectal cancer and hereditary polyposis syndrome and identify patients at high risk of developing hereditary colorectal cancer.
PURPOSE: This research study is collecting information from patients and family members with hereditary colorectal cancer or polyposis syndrome or who are at high risk of developing hereditary colorectal cancer.
Other: study of socioeconomic and demographic variables
Procedure: evaluation of cancer risk factors
Procedure: study of high risk factors
start date: January 2007
estimated completion: June 2017
last updated: August 2, 2017
phase of development: Not Available
size / enrollment: 730
Time Perspective: Prospective
Primary - To identify patients and their family members who have either hereditary colorectal cancer or polyposis syndrome or are at high risk for developing hereditary colorectal cancer.
Secondary - To establish a tissue and data repository that will be used to further research in hereditary colorectal cancer syndromes.
OUTLINE: Data is collected on patients and their families for inclusion in a hereditary colorectal cancer registry. Registry data is entered into a secure database that includes information on patient demographics and medical and family cancer history. The information collected will be used to formulate screening and surveillance recommendations, to further knowledge of hereditary colorectal cancer, and to facilitate cancer research. Registry data will also be used to improve the quality of current standard of care through timely tracking and notification of patients for follow-up care, identification of registry participants at high risk for developing an inherited form of colon cancer, and by serving as a resource for future research. Registry patients may undergo optional blood, urine, and/or sputum sample collection for inclusion in the tissue repository. Tissue samples from a previous biopsy may also be obtained. Samples will be stored for future research studies.
- Identification of patients at high risk of developing hereditary colorectal cancer [ Time Frame: continuous data collection ] [ Designated as safety issue: No ]
Database will continue indefinitely with IRB approval and investigator support
- Establishment of a tissue and data repository [ Time Frame:continuous data collection ] [ Designated as safety issue:No ]
DISEASE CHARACTERISTICS: - Meets any of the following criteria:
1. Patients and family members with a known hereditary colorectal cancer or polyposis syndrome
2. Patients who meet Amsterdam I, II, or Bethesda criteria
3. Patients with a family history suggestive of a hereditary colorectal or polyposis syndrome
4. Patients diagnosed with colorectal cancer at < 50 years old
- Patients are identified through surgical, oncological, gynecological, and gastrointestinal programs, as well as outside referrals, self referral, and the Vanderbilit Tumor Registry
- See Disease Characteristics
PRIOR CONCURRENT THERAPY:
- Not specified
expertly curated content related to this topic
Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal AnastomosesThe primary purpose of this prospective,...
Efficacy and Safety of Eflornithine (CPP-1X)/Sulindac Combination Therapy Versus Each as Monotherapy in Patients wit...BACKGROUND: Molecular studies suggest i...
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates P...Cancer Prevention Pharmaceuticals, Inc. ...
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner SyndromeThe purpose of this study is to assess t...
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Developm...Sucampo Pharmaceuticals, Inc., a global ...
Rofecoxib Reduces Polyp Recurrence in Familial Polyposis.The long-term (mean of 16.4 +/- 4.2 mont...